Common use

Xeloda is an oral chemotherapy medication containing the active ingredient capecitabine, a fluoropyrimidine carbamate that serves as a prodrug for the potent antimetabolite 5-fluorouracil (5-FU). What makes Xeloda particularly innovative as a cancer treatment is its targeted activation mechanism — capecitabine is converted into its active cytotoxic form (5-FU) preferentially within tumor tissue through the action of the enzyme thymidine phosphorylase, which is found in significantly higher concentrations in cancerous cells compared to healthy tissue. This tumor-selective activation means that the systemic exposure of healthy tissues to the cytotoxic effects of 5-FU is minimized, potentially resulting in fewer side effects compared to intravenous 5-FU administration. Xeloda is approved for the treatment of metastatic breast cancer (including types resistant to paclitaxel and anthracycline-based chemotherapy regimens), metastatic colorectal cancer (colon cancer and rectal cancer), and as adjuvant therapy for stage III colon cancer following surgical resection. As a fluoropyrimidine antimetabolite, capecitabine interferes with DNA synthesis in rapidly dividing cancer cells, ultimately leading to cell death. Many patients and oncologists prefer to buy Xeloda online due to its convenient oral administration, which allows patients to receive effective chemotherapy at home rather than requiring frequent hospital visits for intravenous infusions. Xeloda generic versions containing the same capecitabine active ingredient provide an equally effective and more affordable cancer treatment option for patients requiring long-term therapy.



Dosage and direction

Take Xeloda exactly as prescribed by your oncologist — precise adherence to the dosing schedule is critical for the success of your chemotherapy regimen. The standard treatment protocol consists of a 21-day cycle: two weeks of active treatment (days 1-14) followed by a one-week rest period (days 15-21). This treatment cycle is typically repeated for up to eight cycles, though your doctor will determine the optimal number of cycles based on your response to cancer treatment and overall health status. Take capecitabine tablets orally with a full glass of water within 30 minutes after finishing a meal (breakfast and dinner), as food improves absorption and helps reduce gastrointestinal side effects. The recommended daily dose is 2,500 mg per square meter of body surface area per day (2.5 g/m2/day), divided equally between morning and evening doses. Your oncologist will calculate your individual dose based on your body surface area and may adjust it based on your tolerance and any adverse effects experienced. Swallow the tablets whole — do not crush, cut, or chew them. Maintaining consistent timing of your doses is important for sustaining effective drug levels throughout your chemotherapy treatment.



Precautions

While you are receiving Xeloda chemotherapy, it is essential to use highly effective birth control methods, as capecitabine can cause severe harm to a developing fetus. Both female patients and male patients with female partners of childbearing potential should use reliable contraception during treatment and for a period after the last dose. Notify your oncologist if you have any pre-existing liver or kidney disease, as dose adjustments are typically required — patients with moderate renal impairment require a reduced starting dose, and those with severe renal impairment should not receive this cancer treatment. Inform your doctor if you have a history of coronary artery disease or cardiovascular conditions, as capecitabine may increase the risk of cardiac events. It is critical to disclose all concurrent medications, particularly folic acid supplements, blood thinners such as warfarin (Coumadin), phenytoin (Dilantin), and leucovorin (Wellcovorin), as significant and potentially dangerous interactions may occur with this fluoropyrimidine. Your doctor will order regular blood tests throughout your chemotherapy to monitor blood cell counts, liver function, and kidney function — do not miss any scheduled appointments or laboratory tests. Be cautious while driving or operating machinery, as this antimetabolite may cause dizziness, fatigue, or fainting that could impair your ability to perform these activities safely.



Contraindications

Do not start treatment with Xeloda if you have a known allergy or hypersensitivity to capecitabine or fluorouracil (5-FU, Adrucil), as cross-reactivity between these fluoropyrimidine agents is expected. This chemotherapy is strictly contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency — a genetic condition that impairs the body's ability to metabolize fluoropyrimidines, leading to potentially fatal toxicity. DPD testing may be recommended before initiating treatment. Xeloda must not be used during pregnancy or breastfeeding, as capecitabine is a known teratogen. Patients with severe kidney disease (creatinine clearance below 30 mL/min) should not receive this cancer treatment. Adolescents under 18 years of age are not recommended to use this antimetabolite, as safety and efficacy have not been established in this population. Patients who wish to buy capecitabine should always do so under the supervision and prescription of a qualified oncologist.



Possible side effect

Xeloda chemotherapy may cause a range of side effects, some of which can be serious and require immediate medical attention. Notify your oncologist right away if you experience severe vomiting (more than once in 24 hours) or diarrhea (four or more loose stools daily or any nighttime episodes), as dehydration from these effects can be dangerous. Other serious adverse reactions include severe abdominal pain, stomatitis (painful mouth sores and inflammation), constipation, epigastric pain, dyspepsia, dry mouth, flatulence, significant loss of appetite, oral candidiasis (thrush), and hyperbilirubinemia (elevated bilirubin levels). Hand-foot syndrome (palmar-plantar erythrodysesthesia) — characterized by pain, redness, tingling, swelling, and peeling of the skin on the palms and soles — is a hallmark side effect of capecitabine cancer treatment that may require dose modification. Additional serious reactions include fever or flu-like symptoms (which may indicate infection due to lowered white blood cell counts), jaundice, chest pain or angina, sudden numbness or weakness, fainting episodes, itching, signs of dehydration, peripheral edema (swelling of hands and feet), and difficulty breathing. Patients over 80 years of age are more likely to experience severe side effects from this fluoropyrimidine antimetabolite and may require more frequent monitoring and dose adjustments. Report any new or worsening symptoms to your healthcare team promptly, as timely dose modification can help prevent serious complications during your chemotherapy regimen.



Drug interaction

Xeloda has several clinically significant drug interactions that must be carefully managed during cancer treatment. Anticoagulants of the coumarin type (including warfarin) should not be started until at least one month after completing treatment with capecitabine, due to the risk of severe hypocoagulation and potentially life-threatening bleeding — if concurrent anticoagulation is necessary, more frequent INR monitoring is essential. This fluoropyrimidine increases the effects of indirect anticoagulants and elevates blood levels of phenytoin, which may lead to toxicity. Antacids containing aluminum and magnesium hydroxide can increase blood concentrations of capecitabine and its metabolite 5'-deoxy-5-fluorocytidine. Concurrent use with cyclophosphamide may increase toxicity through enhancement of thymidine phosphorylase activity. Calcium folinate (leucovorin) increases the toxicity of capecitabine by potentiating the effects of fluorouracil — this combination requires careful dose management by your oncologist. Allopurinol may reduce the effectiveness of this antimetabolite and should generally be avoided during treatment. Inform your oncology team about all medications, supplements, and herbal products you are taking before beginning Xeloda chemotherapy.



Missed dose

If you miss a dose of Xeloda, take it as soon as you remember, provided it is still within a reasonable time before your next scheduled dose. If it is nearly time for your next intake, skip the missed dose entirely and return to your regular chemotherapy dosing schedule. Do not take a double dose to compensate for the one you missed, as this could increase the risk of serious side effects from this cancer treatment. Contact your oncologist if you miss multiple doses or are unsure how to proceed, as maintaining the proper treatment schedule is important for the effectiveness of your capecitabine therapy.



Overdose

Symptoms of a Xeloda overdose may include severe nausea, vomiting, diarrhea, fever, bloody stools, and coughing up blood. An overdose of this chemotherapy medication is a medical emergency — seek immediate medical attention or contact a poison control center if you suspect you have taken more capecitabine than prescribed. Treatment is supportive and symptomatic, and may include measures to manage dehydration, electrolyte imbalances, and hematological complications. Your medical team will provide appropriate interventions based on the severity of your symptoms.



Storage

Store Xeloda in a dry place away from direct sunlight at room temperature between 15-30 C (59-86 F). Keep the tablets in their original packaging until ready to use to protect them from moisture. Do not store in a bathroom or kitchen where temperature and humidity levels fluctuate. Keep all chemotherapy medications securely out of reach of children, pets, and anyone who is not prescribed this cancer treatment. Handle capecitabine tablets with care and wash hands after handling. Dispose of expired or unused tablets according to your local guidelines for pharmaceutical waste disposal — do not flush or discard in household trash.



Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. The content is intended for educational purposes and should not replace professional medical advice. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.